Headquartered in New York City, Acreage is a vertically integrated, multi-state operator of cannabis ‎licenses and assets in the U.S. Acreage is dedicated to building and scaling operations to create a ‎seamless, consumer-focused branded cannabis experience. Acreage debuted its national retail store ‎brand, The Botanist in 2018 and its award-winning consumer brands, The Botanist and Live Resin Project ‎in 2019.‎

Class E subordinate voting share (each, a “Fixed Share”) of the Company was created pursuant to the Amended Plan of Arrangement.  Each Fixed Share entitles the holder to one vote per share at shareholder meetings of the Company. Each Fixed Share is subject to an option (the “Canopy Option”) in favour of Canopy Growth Corporation (“Canopy Growth”) pursuant to which Canopy Growth may, upon satisfaction or waiver of the conditions set out in the Amended Arrangement Agreement, acquire the Fixed Shares (the “Acquisition”).  The  Canopy Option is required to be exercised upon the occurrence of changes in U.S. federal law to permit the general cultivation, distribution, and possession of marijuana and subject to the satisfaction or waiver of certain conditions to closing as set out in the Amended Arrangement Agreement, the Acquisition will be completed.

Investor Note: In addition to the 71,343,094 Fixed Shares and 30,626,805 Floating Shares that are listed and trading, there are 17,017,664 Fixed Shares and 7,242,885 Floating Shares, respectively, reserved for issuance pursuant to redemption and conversion rights attached to other share classes of Acreage Holdings, Inc., as well as certain outstanding securities of Acreage Holdings WC, Inc. and High Street Capital Partners, LLC, which are subsidiaries of Acreage Holdings, Inc. The total number of Fixed Shares and Floating Shares, as converted, is 88,360,758 and 37,869,690, respectively, excluding options, warrants, RSUs and convertible debt.

Founded in 2014, Adastra Holdings Ltd. through its Health Canada licensed subsidiary, Adastra Labs has built a successful reputation as a leading cannabis processor. Adastra manufactures products for its successful in-house concentrates brands Phyto Extractions and Endgame Extracts and co-manufactures for many Canadian cannabis brands. With products sold at more than 2,000 retailers across the country.

Operating out of its 13,500 sq. ft. Health Canada Licensed Standard Processing and co-located analytical testing lab facility, Adastra produces and distributes cannabis-derived products designed for medical cannabis and forward-looking therapeutic use. 

Adastra received its controlled substances dealer's license in August 2022 with an amendment in February 2023 and is licensed to partner with healthcare professionals and practitioners within the regulated environment to help create efficacious remedies that address the actual needs of patients.

L'émetteur est un fournisseur de solutions de santé numériques utilisant une combinaison exclusive de dispositifs de surveillance numérique de la santé, de logiciels basés sur l'IA et d'une plate-forme de cloud computing qui se combinent pour aider les soignants, les patients et les professionnels de la santé à accéder et à utiliser les données de santé pertinentes.

Albert Labs International Corp. is a clinical research and laboratory-based drug development company serving the needs of mental health care. Through a succinct, real-world evidence (RWE)-driven clinical journey, Albert Labs seeks to commercialize its psychedelic-based treatments and, in doing so, bring psychedelic-assisted psychotherapy to patients sooner. Focused on accelerating access and faster approvals, Albert Labs prioritizes patients with urgent and unmet needs by developing licensed drugs to treat a variety of mental health conditions. Cancer-related distress, an original goal of Albert Labs' development program, is thought to affect more than 16 million patients worldwide.